Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

17.86 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

20 21 Next >

Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook

May 11, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

April 27, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations

April 26, 2023

From Corza Medical Inc.

Via GlobeNewswire

Takeda Pharmaceutical Ltd. (NYSE: TAK) Highlighted for Surprising Price Action

April 06, 2023

Via Investor Brand Network

Cannabis Movers & Shakers: Latest Appointments From Khiron, MariMed, Equilibria & More ↗

April 25, 2023

Equilibria Strengthens Women's Wellness With New CSO

Via Benzinga

Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday ↗

April 25, 2023

The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.

Via The Motley Fool

This Supercharged Dividend King Stock Might Soon Run Out of Steam ↗

April 25, 2023

Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.

Via The Motley Fool

United Nations' Specialized Agency In Preliminary Talks With Takeda For Dengue Vaccine, Currently Under FDA Review ↗

April 21, 2023

The Pan American Health Organization (PAHO) is reportedly in early talks with Takeda Pharmaceutical Co Ltd (NYSE: TAK) regarding the potential orders of its dengue vaccine, TAK-003.

Via Benzinga

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

April 17, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children

April 11, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

April 11, 2023

We're starting off the day with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on Tuesday!

Via InvestorPlace

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders

April 11, 2023

From Centogene NV

Via GlobeNewswire

Zoetis Stock Shows Healthy Growth Along With Puppies, Kittens ↗

April 10, 2023

Zoetis stock is trying to complete a flat base with a 176.76 buy point. See if it can break out. Its stock got an upgrade Monday

Via Investor's Business Daily

Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal ↗

April 08, 2023

Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up...

Via Talk Markets

The Byzantine Adderall Shortage Puts Teva And Others In The Hot Seat ↗

April 05, 2023

Millions of people are scrambling to get their ADHD medication. Here's why.

Via Investor's Business Daily

Etsy To Rally Around 30%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

April 04, 2023

B of A Securities cut the price target for Stem, Inc. (NYSE: STEM) from $9 to $5. B of A Securities analyst Julien Dumoulin-Smith downgraded the stock from Neutral to Underperform. Stem shares fell...

Via Benzinga

Takeda Announces New U.S. Corporate Social Responsibility (CSR) Program Partners

April 03, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

March 30, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine

March 30, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

March 30, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Zoetis Stock Sees IBD Relative Strength Rating Improve To 73 ↗

March 27, 2023

Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for.

Via Investor's Business Daily

BioLife Plasma Services Opens its 200th Plasma Donation Center in the U.S.

March 27, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Week In Review: HighlightLL Pharma Out-Licenses Parkinson's Treatment To Biohaven For $970 Million ↗

March 25, 2023

HighlightLL Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. Biohaven will have global rights to the product...

Via Talk Markets

Price Growth & Yield: For That Magical Combo, Leave the U.S.

March 21, 2023

Three foreign stocks, Takeda Pharmaceutical, United Microelectronics, and Coca-Cola FEMSA are showing that magical combination of growth and yield.

Via MarketBeat

Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says ↗

March 20, 2023

Via Benzinga

Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis

March 18, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) Sets New 52-Week High in Friday Session

March 17, 2023

Via Investor Brand Network

Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023 ↗

March 16, 2023

Via Benzinga

Johnson & Johnson's Experimental Dengue Pill Shows Efficacy In Animal Studies ↗

March 15, 2023

Via Benzinga

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

March 14, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.